AKT1 and ulcerative colitis: It can be inferred that TFPV may enhance the intestinal barrier function and reduce the expression of pro-inflammatory cytokines by inhibiting PI3K/AKT/NF-κB and IL-17 signaling pathways, thus alleviating the ulcerative colitis in mice induced by DSS.